media – Page 54 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Acelyrin’s izokibep for hidradenitis suppurativa reveals positive results

Acelyrin has shared positive results from a late-stage study of its IL-17A inhibitor izokibep in hidradenitis suppurativa (HS), but has said it will not be moving forward with the asset in this indication. Estimated to affect about 1% of the population in most studied countries, HS is a chronic inflammatory skin condition that causes painful nodules and abscesses. In the phase 3 trial, izokibep demonstrated statistically significant responses across multiple efficacy endpoints at week 12, with 33% of patients being treated with izokibep 160mg weekly achieving at least a 75% reduction in total abscess and inflammatory nodule count (HiSCR75) compared to 21% of those receiving placebo. Results also showed that 25% and 22% of izokibep-treated patients achieved HiSCR90 and HiSCR100, respectively, compared to 9% and 8% in the placebo cohort. The announcement comes shortly after the drug demonstrated promising results in a phase 2b/3 study for psoriatic arthritis (PsA), a ...
- Source: drugdu
- 66
- August 30, 2024
【EXPERT Q&A】What are Radioactive Drug Conjugates (RDCs)?

Drugdu.com expert’s response: Radioactive Drug Conjugates (RDCs) represent a novel class of therapeutic agents that combine the strengths of precise targeting and potent killing capabilities. By linking radioactive nuclides to ligands (such as antibodies, peptides, small molecules, etc.) through linkers and chelators, RDCs achieve precise localization and effective eradication of target cells. Below, I will elaborate on RDCs from four aspects: definition and structure, advantages and applications, classification, as well as challenges and prospects. I. Definition and Structure Definition: RDCs are drug formulations that integrate radioactive nuclides with targeting molecules (ligands) through linker arms (connectors), aimed at delivering precise strikes against tumor or other disease targets. Structure: RDC drugs consist primarily of targeting ligands, linker arms, chelators, and nuclide conjugates. The targeting ligands recognize and bind to specific target cells or tissues; linker arms connect the targeting ligands to the radioactive nuclides; chelators stabilize the radioactive nuclides, preventing their premature ...
- Source: drugdu
- 69
- August 30, 2024
Ansukang Ultrasonic Knife completes a new round of billion yuan financing

Today (August 26th), Ansukang Medical (Suzhou) Co., Ltd. (hereinafter referred to as “Ansukang Medical”) announced the completion of a new round of 100 million yuan financing. The round of financing is jointly invested by Taiping Innovation, Junlian Capital, and Shengjing Jiacheng. The funds raised from the financing will mainly be used for promoting the market of unmanned ultrasonic knives, building a new generation of energy platforms, and preparing production capacity. Founded in 2020, Ansukang Medical has been focusing on the research and development of innovative medical devices since its establishment. It is an innovative medical device company based on its own core technology system, committed to providing Chinese medical workers with better and more convenient medical devices. At present, the main product launched by Ansukang Medical is the new generation of non host ultrasonic knife, which is also the world’s first split type non host ultrasonic knife. Compared with similar ...
- Source: drugdu
- 107
- August 29, 2024
Balance Medical creates a new era of TAVR2.0

On August 22nd, the National Medical Products Administration announced that it has recently approved the registration applications for two innovative products, the “Transcatheter Aortic Valve System” of Beijing Balance Medical Technology Co., Ltd. (hereinafter referred to as “Balance Medical”). The transcatheter aortic valve system is mainly used to treat aortic valve stenosis, and there are two main treatment options: surgical thoracotomy for valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR). TAVR can be roughly divided into ball expanding and self expanding instruments. Compared to SAVR, TAVR has the characteristics of no need for thoracotomy and extracorporeal circulation, minimal trauma, and fast recovery, providing a safer treatment option for high-risk surgical patients. However, in the Chinese market, the penetration rate of TAVR is still relatively low, far below the global level, and a large amount of demand has not been met, with broad prospects. According to Frost&Sullivan data, there were ...
- Source: drugdu
- 74
- August 29, 2024
CPhI North America

Organiser: Informa Markets Time: 20 – 22 May 2025 Address: 1101 Arch Street, Philadelphia, PA 19107, United States Exhibition hall: Pennsylvania Convention Center Product range: Active Pharmaceutical Ingredients (APIs): Vitamins, Hormones, Sulfonamides, Antipyretics and Analgesics, Tetracyclines, Amino Acids and their Derivatives, Chloramphenicols, Digestive System Medications, Other Anti-infectives, Penicillins, Aminoglycosides, Lincomycin, Cardiovascular System Medications, Antiparasitic Drugs, Cephalosporins, Macrolides, Respiratory System Medications, Central Nervous System Medications, Other Western Medicine APIs Packaging Equipment: Pharmaceutical Machinery, Packaging Machinery, Packaging Materials, Pharmaceutical Production Equipment and Technology, Pharmaceutical Packaging Equipment, Pharmaceutical Packaging Materials, Pharmaceutical Production, Sterilization and Laboratory Instrument Systems Pharmaceutical Products: Various Chinese Patent Medicines, Western Medicines, New Drugs, APIs, Chemical Pharmaceuticals, Pharmaceutical Intermediates, Biopharmaceuticals, Traditional Medicines, Chinese Medicines, Herbal Medicines, Extracts from Animals and Plants, Veterinary Drugs, Food Ingredients and Additives, etc. About CPhI North America： CPhI North America is one of the largest and most authoritative pharmaceutical ingredients exhibitions in North America. The CPhI series of ...
- Source: drugdu
- 230
- August 29, 2024
Eli Lilly’s Zepbound to be issued in single-dose vials for self-payers

Eli Lilly and Company has announced the availability of Zepbound (tirzepatide) in 2.5mg and 5mg single-dose vials for self-pay for adults with obesity. The move significantly expands the supply of Zepbound in response to high demand and offers a more affordable option for those who self-pay. The vials are priced a minimum of 50% lower than the list price of other incretin medicines for obesity. Lilly has introduced a new self-pay pharmacy component within LillyDirect, enabling patients with a valid prescription to purchase Zepbound directly. The initiative ensures the authenticity of the medicine and safeguards patients from counterfeit products. Lilly also announced its commitment to ensuring that Zepbound is used appropriately and not for cosmetic weight loss, implementing a multi-step verification process for dispensing. The 2.5mg Zepbound vial costs $399 for a four-week supply while the 5mg dose costs $549 – both representing significant savings compared to other treatments. The ...
- Source: drugdu
- 59
- August 29, 2024
Pfizer launches digital healthcare platform to streamline access

Pfizer has launched a new digital platform, PfizerForAll, aimed at simplifying the process of accessing healthcare for millions of Americans. The platform provides an integrated experience for managing health and wellness, particularly for those affected by common illnesses and seeking adult vaccinations. PfizerForAll consolidates critical resources and services, enabling individuals and families to take health actions such as obtaining care, filling prescriptions and finding potential savings on Pfizer medicines. The platform operates within the US healthcare system and is developed in partnership with healthcare organisations. Patients using PfizerForAll can leverage their existing insurance and pharmacy programmes while benefiting from new direct services from partners such as UpScriptHealth, Alto Pharmacy and Instacart. At its inception, PfizerForAll offers same-day appointments with healthcare professionals for in-person or telehealth consultations, home delivery of prescription medicines, and scheduling for adult vaccinations against Covid-19, flu, RSV [respiratory syncytial virus] and pneumococcal pneumonia. The platform will also ...
- Source: drugdu
- 71
- August 29, 2024
MHRA approves Astellas’ Vyloy combination for gastric cancer

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Astellas Pharma’s Vyloy (zolbetuximab) as part of a first-line combination treatment for a subset of gastric cancer patients. The monoclonal antibody has been authorised for use alongside chemotherapy to treat adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are claudin 18.2 positive. In the UK, adenocarcinomas, which develop from cells in the innermost lining of the stomach, account for most cases of gastric cancer, with around 6,600 people diagnosed every year. Most cases go undetected until an advanced stage, as the disease rarely causes early symptoms and tends to develop slowly over a number of years. Vyloy is now the only licensed treatment to target the claudin 18.2 protein, which is expressed in gastric, oesophageal, lung and ovarian tissues, and is administered intravenously every two to three ...
- Source: drugdu
- 61
- August 29, 2024
Improving tracking of AMR bacteria in hospitals using new genomic technique

Using a genomic approach, researchers have developed a way to simultaneously track the spread of multiple common antibiotic-resistant bacteria in hospitals. Current methods culture and sequence all pathogens separately so the new sequencing technique could help to prevent and manage hospital infections more quickly and effectively. Published in the Lancet Microbe, the proof-of-concept study from the Wellcome Sanger Institute, the University of Oslo, Fondazione IRCCS Policlinico San Matteo in Italy and collaborators captured the whole population of pathogenic bacteria found in the gut, upper airways and lungs of patients in multiple hospital intensive care units (ICUs) and ordinary wards during the first wave of the COVID-19 pandemic in 2020. The team found that, with most ICU patients colonised by several treatment-resistant bacteria and all patients colonised by at least one, they were able to determine which type of bacteria each patient had. Antimicrobial resistance (AMR) occurs when bacteria, viruses, fungi ...
- Source: drugdu
- 67
- August 29, 2024
AI-Based Digital Pathology Platform Improves Lung Cancer Diagnosis

Lung cancer ranks among the most prevalent and fatal cancers worldwide. Current treatment strategies for lung cancer patients rely on pathological examinations, which can reveal genetic mutations specific to the patient’s cancer, facilitating personalized treatment approaches. Over the last few years, pathology has evolved dramatically due to digital advancements, making traditional microscopes obsolete. Tissue samples are now digitized and analyzed via computer screens, which is essential for employing sophisticated artificial intelligence (AI)-based analytical methods. These AI technologies can extract additional insights from pathological tissue sections that were previously unattainable. A team of researchers at the University of Cologne (Cologne, Germany) has developed an AI-driven digital pathology platform that can revolutionize the analysis of lung cancer tissues. This platform utilizes newly developed algorithms to perform fully automated examination of digitized lung cancer tissue sections, offering faster and more precise analyses than traditional methods. Detailed in their publication in the journal Cell ...
- Source: drugdu
- 67
- August 28, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.